[Aspergillus bronchitis and aspergilloma treated successfully with voriconazole].
BACKGROUND
Aspergillus fumigatus is a ubiquitous soil-dwelling organism, which can cause both aspergillomas which develop in a preformed lung cavity, and aspergillus bronchitis. The two pathologies can occasionally co-exist, notably in patients with of cystic fibrosis.


METHODS
We describe a 57 year old patient, with diffuse bronchiectasis, who developed aspergillus bronchitis as well as an aspergilloma complicating a cavity caused by an atypical mycobacterial infection. After one month of therapy with voriconazole the aspergilloma had decreased in size and the endobronchial changes had resolved.


CONCLUSIONS
This case report illustrates that in addition to its established role for the treatment of invasive aspergillosis, voriconazole is a promising new therapy for the treatment of aspergilloma and aspergillus bronchitis.
Freymond
N
N
Service de Pneumologie et d'Immunologie Clinique, Centre Hospitalier Lyon Sud, Pierre Bénite, France. nathalie.freymond@chu-lyon.fr
Le Loch
J-B
JB
Devouassoux
G
G
Harf
R
R
Rakotomalala
A
A
Pacheco
Y
Y
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole